Trial Profile
A Clinical Evaluation of the Everolimus Eluting Bioresorbable Vascular Scaffold System (BVS) for the Treatment of Subjects With Critical Limb Ischemia (CLI) From Occlusive Vascular Disease of the Tibial Arteries
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2019
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Chronic limb-threatening ischemia; Peripheral ischaemia; Restenosis
- Focus Therapeutic Use
- Acronyms ABSORB BTK
- Sponsors Abbott Laboratories
- 24 May 2014 New trial record